Do you recommend hypofractionated radiotherapy for elderly and/or poor KPS patients with diffuse IDH-mutant grade 2 glioma by extrapolation from high-grade glioma trials?
Is there any data to suggest higher risk of malignant transformation with hypofractionation? Does concurrent Temozolomide change your approach?
Answer from: Radiation Oncologist at Academic Institution
I am not aware of any trial for this specific scenario. However, hypo-fractionated radiotherapy with a higher dose per fraction and a lower total dose (for example, the Rao regimen of 15 × 2.67 Gy) is appropriate in older patients (>65–70 years of age) and in thos...